At the Edge of a Miracle: The Hepatitis C Virus (HCV) Epidemic in Malaysia
The hepatitis C virus (HCV) has long since been a neglected disease. However, of late, given the development of revolutionary drugs called direct-acting antivirals (DAAs) that can cure the disease in as little as 8 weeks, international interest, and with it, international financial investment, has peaked.
When we began this project, we realised that there was little consolidated information on the HCV situation in Malaysia, whether epidemiological reports, patient voices, or the diagnostics and treatment environment. This report seeks to fill that gap and be a useful tool for clinicians, civil society, policymakers, politicians, and other stakeholders working towards access and affordability of HCV diagnostics and medication.
100% LIFE – 2018 Annual Report
Our partner, 100% LIFE, is the largest patient organization in Ukraine.
100% LIFE employs a range of strategies in order to achieve the 90-90-90 targets, including increasing quality medical and social support, and advocating on key issues, such as improving the patent law and taking action to decrease stigma-related treatment barriers.
In 2018, the organization’s activities, saved the country’s health budget 359 million (UAH) on the public procurement of HIV drugs due to optimizing the procurement plan, and 100 million (UAH) was saved on the public procurement of TB drugs due to the optimization of procurement nomenclature.
Download: 100% LIFE – 2018 Annual Report.
LACTA Community Advisory Board (CAB) – 2018 Report
Treatment activists, representing 13 countries in the Latin America and Caribbean region (LACTA), met with ViiV Healthcare in Panama City (22-23 October 2018) to push the company on the price discrepancies for HIV treatment and a lack of negotiation across the region, along with other barriers to access.
Read the report in full, including the Q&As with ViiV Healthcare and the Medicines Patent Pool.